Publications

Researchers performed pooled CRISPR-Cas9, RNAi loss-of-function and a small-molecule screens to identify CDK4 and XPO1 as potential therapeutic targets in undifferentiated sarcoma. This approach integrates new patient-derived models to facilitate the discovery of new targets.

The authors found that within regions of copy-number gain, CRISPR/Cas9 targeting of both expressed and unexpressed genes, as well as intergenic loci, led to significantly decreased cell proliferation through induction of a G2 cell-cycle arrest. 

Researchers show proof of principle that somatic genomic rearrangements can be identified from whole-exome sequencing data, and characterize the oncogenic properties of two fusion proteins.

Investigators use a pooled in vivo screen determine the transforming abilities of mutant alleles identified in 5,338 tumors.

A new computational method links genetic alterations to functional phenotypes such as transcriptional activation.

Computational analysis of an RNAi screen in non-small cell lung cancer cell lines reveals potential targets.